“In-silico exploration of cyanobacterial bioactive compounds for managing diabetes: Targeting alpha-amylase and beta-glucosidase”

Abstract

This research investigates the potential of bioactive compounds derived from cyanobacteria as inhibitors of alpha-amylase and beta-glucosidase enzymes, which are involved in starch digestion and glucose release. The study reveals strong molecular interactions between these compounds and the enzyme active sites through docking analysis. Notably, compounds such as Abietic, Anilide, Nostocarboline, Noscomin, Tanikolide, Tubercidin, Cryptophycin, and Cyanobacteria exhibit the lowest binding energies when interacting with alpha-amylase. Among them, Noscomin demonstrates the lowest docking score and binding energy against alpha-amylase, outperforming the reference compound metformin. Similarly, these compounds also display low binding energies when interacting with beta-glucosidase. The bioactive compounds from cyanobacteria show significant potential as inhibitors of alpha-amylase and beta-glucosidase, suggesting their efficacy in managing diabetes by slowing down starch digestion and controlling glucose release. Their superior binding affinities and lower binding energies, particularly Noscomin, indicate their potential in regulating blood sugar levels by interacting effectively with these enzymes. Thus, these compounds hold promise as valuable leads for developing alpha-amylase and beta-glucosidase inhibitors, contributing to the management of diabetes. Further research is required to understand the underlying mechanisms of action and assess the bioavailability, toxicity, and pharmacological potential of these cyanobacterial compounds. This investigation provides valuable insights into the potential of cyanobacterial bioactive compounds as effective candidates for the development of novel therapeutics targeting alpha-amylase and beta-glucosidase enzymes in diabetes management.

Keywords

Diabetes / Cyanobacteria / Bioactive compounds / Molecular docking / Alpha-amylase and beta-glucosidase

References

[1] Published. International Diabetes Federation (9th Editio). Diebetes, Atlas; 2019. https://diabetesatlas.org/atlas/ninth-edition/. Accessed February 24, 2022.

[2] Basit A , Fawwad A , Qureshi H , et al. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016-2017. BMJ Open. 2018;8(8). https://doi.org/10.1136/BMJOPEN-2017-020961.

[3] Ahlqvist E , Ahluwalia TS , Groop L . Genetics of type 2 diabetes. Clin Chem. 2011; 57 (2): 241- 254.

[4] Khanam A , Ahmad S , Husain A , Rehman S , Farooqui A , Yusuf MA . Glycation and antioxidants: hand in the glove of antiglycation and natural antioxidants. Curr Protein Pept Sci. 2020; 21 (9): 899- 915.

[5] Elosta A , Ghous T , Ahmed N . Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev. 2012; 8 (2): 92- 108.

[6] Husain A , Farooqui A , Khanam A , et al. Physicochemical characterization of Cphycocyanin from Plectonema sp. and elucidation of its bioactive potential through in silico approach. Cell Mol Biol. 2022;67(4):68–82. https://doi.org/10.14715/cmb/2021.67.4.8.

[7] Kaushik A , Sangtani R , Parmar HS , Bala K . Algal metabolites: paving the way towards new generation antidiabetic therapeutics. Algal Res. 2023: 69.

[8] Husain A , Alouffi S , Khanam A , Akasha R , Farooqui A , Ahmad S . Therapeutic efficacy of natural product ‘C-phycocyanin’ in alleviating streptozotocin-induced diabetes via the inhibition of glycation reaction in rats. Int J Mol Sci. 2022; 23 (22): 14235.

[9] Li Z , Tian J , Cheng Z , et al. Hypoglycemic bioactivity of anthocyanins: a review on proposed targets and potential signaling pathways. Crit Rev Food Sci Nutr. 2022. https://doi.org/10.1080/10408398.2022.2055526. Published online.

[10] Vijayakumar S , Menakha M . Pharmaceutical applications of cyanobacteria-A review. J Acute Med. 2015; 5 (1): 15- 23.

[11] Swain SS , Paidesetty SK , Padhy RN . Antibacterial, antifungal and antimycobacterial compounds from cyanobacteria. Biomed Pharmacother. 2017; 90: 760- 776.

[12] Murray M , Dordevic AL , Ryan L , Bonham MP . An emerging trend in functional foods for the prevention of cardiovascular disease and diabetes: marine algal polyphenols. Crit Rev Food Sci Nutr. 2018; 58 (8): 1342- 1358.

[13] Dirir AM , Daou M , Yousef AF , Yousef LF . A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes. Phytochemistry Rev. 2022;21(4):1049–1079. https://doi.org/10.1007/s11101-021-09773-1.

[14] Kaur N , Kumar V , Nayak SK , Wadhwa P , Kaur P , Sahu SK . Alpha-amylase as molecular target for treatment of diabetes mellitus: a comprehensive review. Chem Biol Drug Des. 2021; 98 (4): 539- 560.

[15] Ibrahim A , Umar IA , Aimola IA , Mohammed A . Inhibition of key enzymes linked to diabetes by Annona senegalensis Pers (Annonaceae) leaf in vitro. J Herb Med. 2019; 16. https://doi.org/10.1016/j.hermed.2018.11.004.

[16] Khanam A , Ahmad S , Husain A . A perspective on the impact of advanced glycation end products in the progression of diabetic nephropathy. Curr Protein Pept Sci. 2022; 24(1):2–6. https://doi.org/10.2174/1389203724666221108120715.. Curr Protein Pept Sci. 2022; 24 (1): 2- 6.

[17] Sharifuddin Y , Chin YX , Lim PE , Phang SM . Potential bioactive compounds from seaweed for diabetes management. Mar Drugs. 2015; 13 (8): 5447- 5491.

[18] Bishoyi AK , Sahoo CR , Padhy RN . Recent progression of cyanobacteria and their pharmaceutical utility: an update. J Biomol Struct Dyn. 2022. https://doi.org/10.1080/07391102.2022.2062051. Published online.

[19] Alouffi S , Khanam A , Husain A , Akasha R , Rabbani G , Ahmad S . D-ribose-mediated glycation of fibrinogen: role in the induction of adaptive immune response. Chem Biol Interact. 2022;367(August):110147. https://doi.org/10.1016/j.cbi.2022.110147.

[20] Rizvi SMD , Shakil S , Haneef M . A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J. 2013; 12: 831- 857.

[21] Biovia Dsv . No Title. 2021. Published online.

[22] Khanam A , Alouffi S , Rehman S , Ansari IA , Shahab U , Ahmad S . An in vitro approach to unveil the structural alterations in d-ribose induced glycated fibrinogen. J Biomol Struct Dyn. 2021; 39 (14): 5209- 5223.

[23] Alouffi S , Khanam A , Husain A , Akasha R , Rabbani G , Ahmad S . D-ribose-mediated glycation of fibrinogen: role in the induction of adaptive immune response. Chem Biol Interact. 2022;367. https://doi.org/10.1016/j.cbi.2022.110147.

[24] Husain A , Alouffi S , Khanam A , et al. Non-inhibitory effects of the potent antioxidant C-phycocyanin from Plectonema sp. on the in vitro glycation reaction. Rev. Rom. Med. Lab. 2022;30:199–213. https://doi.org/10.2478/rrlm-2022-0018..

[25] Husain A , Khan F , Osama K , et al. Media optimization for c-phycocyanin production in Plectonema sp. using response surface methodology and central composite design. International Journal of Research in Pharmaceutical Sciences. 2020;11(3):3897–3904..

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).